#United States #Cambridge #MetaVia #Obesity Treatment #DA-1726

MetaVia's Patent Strategy:

MetaVia Inc., a clinical-stage biotechnology firm, has recently announced a significant milestone in the development of its lead asset, DA-1726—a novel treatment aimed at tackling obesity and related metabolic disorders. The company has established a comprehensive global patent portfolio that consists of 39 granted and pending patents both in the U.S. and internationally.

This robust intellectual property protection is crucial as it ensures that the unique peptide structure of DA-1726, a dual oxyntomodulin analogue, is safeguarded until at least 2041. Founded on licensing agreements with Dong-A ST Co., Ltd., MetaVia's patent estate not only covers the core molecule but also its therapeutic applications, which solidify the company's market positioning in one of the rapidly expanding sectors in healthcare.

The Innovation Behind DA-1726:

DA-1726 stands out because it functions as a dual agonist targeting glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), leading to a reduced appetite and increased energy expenditure. This dual-action mechanism is expected to deliver superior weight-loss results compared to existing treatments. Preliminary clinical data suggest promising outcomes, with a significant weight loss of around 9% observed at the 48 mg dosing level, along with substantial improvements in waist circumference and blood sugar control.

CEO Hyung Heon Kim emphasized the strategic importance of solidifying MetaVia's patent foundation as they push forward with DA-1726. He stated, "Building a strong and durable patent foundation is essential as we advance DA-1726 as a potential best-in-class therapy for obesity and metabolic disease."

Clinical Trials and Future Directions:

Looking towards the future, MetaVia is planning extensive 16-week titration studies that will test higher doses of DA-1726, specifically 48 mg and 64 mg. The results from these studies, expected by the fourth quarter of 2026, could unlock greater value and foster further advancement through later-stage clinical developments.

The pre-clinical studies involving DA-1726 showed that it may outpace other pharmaceutical treatments in both effectiveness and safety, indicating a solid potential for becoming a preferred choice among patients and healthcare providers.

About MetaVia Inc.:

MetaVia Inc. has positioned itself at the forefront of combating cardiometabolic diseases. In addition to DA-1726, the company is also developing another treatment, vanoglipel (DA-1241), which targets Metabolic Dysfunction-Associated Steatohepatitis (MASH). The innovative nature of both drugs revolves around leveraging naturally occurring hormones to enhance efficacy in weight management and metabolic health.

For those looking to understand more about MetaVia's range of therapies, the ongoing research is expected to not only provide insights on weight loss strategies but also on overall metabolic health improvements. As the medical landscape continues to evolve, MetaVia’s commitment to pioneering new treatments showcases its dedication to advancing healthcare solutions for obesity and related disorders.

In conclusion, with the patent and clinical milestones in place, MetaVia's DA-1726 stands as a competitive and promising solution in the obesity therapy domain, paving the way for potential breakthroughs in managing one of the foremost public health crises of our time.